Observational studyAmerican journal of hypertension2026
Long-term SBP time in target and risk of cardiovascular events in older adults: a secondary analysis of the ASPREE cohort.
Observational study in American journal of hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundBP time in target range (TTR) predicts cardiovascular disease (CVD) in high-risk populations; however, TTR's predictive utility in older adults without prior CVD is uncertain.
methodsWe performed a post hoc analysis of the ASPirin in Reducing Events in the Elderly trial and its observational follow-up. SBP TTR for <140 and <130 mm Hg was estimated for each participant using BPs from the first 3 visits. Participants with 0% or 100% TTR were categorized separately, and remaining participants grouped into tertiles using linear interpolation to estimate TTR. Cox proportional hazards models evaluated associations between TTR and adjudicated incident CVD and major adverse cardiovascular events (MACE) after the TTR estimation period, with 0% TTR as reference.
resultsAmong 16,730 predominantly White Australian adults (mean age, 74 years) followed for a mean of 7.7 years after TTR estimation, 100% TTR <140 mm Hg had reduced risk of CVD (HR, 0.81; 95% CI, 0.68-0.96; P = .01), while 100% TTR <130 mm Hg had reduced risks of CVD (HR, 0.82; 95% CI, 0.67-0.99; P = .04) and MACE (HR, 0.72; 95% CI, 0.57-0.91; P < .01). Associations were strongest among women, antihypertensive users, frail/pre-frail participants, and those younger than median age. Findings were consistent after adjusting for competing risk of non-CVD death, when the TTR estimation period was extended an additional year, and when estimated using proportion of individual visit BPs at target.
conclusionsLonger SBP TTR was associated with reduced risk of cardiovascular events in older adults, underscoring the importance of sustained BP control with aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.